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Abstract: Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately
affect those with hypertension and diabetes. Because of inadequate methods in published systematic
reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19
patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected
observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted
data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of
evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias.
Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10-15; n = 12
870; I 2: 89%), and 17% (95% CI, 13-22; n = 12 709; I 2: 95%), respectively. In severe Covid-19, the
prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I 2: 0%) and 32% (95% CI,
16-54; n = 1078; I 2: 63%), respectively. Unadjusted relative risk for intensive care unit admission and
mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I 2: 80%; P = .008) and 2.78 (95% CI, 1.39-5.58; n
= 2058; I 2: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; I 2: 0%; P < .001)
and 2.39 (95% CI, 1.54-3.73; n = 3107; I 2: 66%; P < .001) for hypertensives. Neither diabetes (1.50;
95% CI, 0.90-2.50; n = 1991; I 2: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; n = 2023;
I 2: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit
admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased
compared with those without these comorbidities.
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Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately 
affect those with hypertension and diabetes. Because of inadequate methods in published system-
atic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in 
Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, 
and selected observational peer-reviewed studies in English of patients with Covid-19. Independent 
reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, 
and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate 
to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence in-
terval [CI], 10-15; n = 12 870; I2: 89%), and 17% (95% CI, 13-22; n = 12 709; I2: 95%), respectively. In 
severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16-20; n = 1099; I2: 
0%) and 32% (95% CI, 16-54; n = 1078; I2: 63%), respectively. Unadjusted relative risk for intensive 
care unit admission and mortality were 1.96 (95% CI, 1.19-3.22; n = 8890; I2: 80%; P = .008) and 2.78 
(95% CI, 1.39-5.58; n = 2058; I2: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18-3.99; n = 1737; 
I2: 0%; P < .001) and 2.39 (95% CI, 1.54-3.73; n = 3107; I2: 66%; P < .001) for hypertensives. Neither di-
abetes (1.50; 95% CI, 0.90-2.50; n = 1991; I2: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99-2.23; 
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n = 2023; I2: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive 
care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 
is increased compared with those without these comorbidities.
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Coronavirus disease 2019 (Covid-19) is the worst pandemic in the past 100 years span-
ning more than 200 countries [1] and affecting millions of individuals worldwide [2]. The 
novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) was identified as the 
causative agent of Covid-19, with angiotensin-converting enzyme 2 (ACE2) as one of its 
cellular receptors [3]. Covid-19 has a spectrum of clinical manifestations ranging from 
asymptomatic or mildly symptomatic in about 80% of those affected according to commu-
nity surveys to an approximate 2% case fatality rate in the hospitalized populations [4-7]. 
Although the statistical estimations are changing daily, more than 11 million people have 
been affected by Covid-19, resulting in more than half a million deaths across the world by 
July 7, 2020 [1, 6].
A great risk of severe Covid-19 has been reported in patients with diabetes and hyper-
tension [8]. One study of 191 patients reported a mortality risk of 2.85-fold and 3.05-fold for 
those with diabetes and hypertension, respectively [9]. Furthermore, the Chinese Center for 
Disease Control reported a higher case fatality rate for persons with diabetes compared with 
those without (7.3%. vs 2.3%, respectively) [7]. This risk may be explained by a dysregulated 
immune response, a higher comorbidity burden, and alterations of ACE2 cellular expres-
sion [6, 10-12]. The latter has been the subject of intense scrutiny, given the lack of evidence 
against the use of renin-angiotensin system blocking agents and their known benefits in di-
abetes and hypertension [12-14], as well as other cardiovascular conditions that have been 
shown to enhance ACE2 expression [15].
Previous systematic reviews reported a prevalence of diabetes and hypertension in 
patients with Covid-19 ranging from 9.7% to 11.9% and 17.1% to 20%, respectively [16-19]. 
The risks of severe Covid-19 in patients with diabetes and hypertension were ~3 and ~2-fold, 
respectively [16-18, 20]. However, these reports failed to address the high probability of in-
cluding repeated information and patient duplicates in the analysis and thus may lead to 
inaccurate effect sizes and misleading results [16, 18-21]. This has been listed by authors 
as a major limitation [20], and has raised major editorial concerns [22-24]. Ultimately, risk 
estimates remain uncertain. Therefore, we systematically assessed the prevalence of dia-
betes and hypertension in patients with Covid-19 after excluding repeated patients across 




This systematic review adheres to the standards set in the Meta-analysis of Observational 
Studies in Epidemiology and Preferred Reported Items for Systematic Reviews and Meta-
Analysis [25, 26]. Registration ID is CRD42020176582 and is available at: https://www.crd.
york.ac.uk/prospero/display_record.php?RecordID=176582.
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Eligibility criteria
For our first aim, we included observational and interventional studies that reported the 
frequency of diabetes and/or hypertension in adult population with Covid-19. For our second 
aim, we included studies that reported exposure-outcome association as univariate or mul-
tivariate analysis, with diabetes, hypertension being the exposure, and severe Covid-19 
through ICU admissions or mortality being the outcome of interest. We excluded case reports 
(n < 2) and studies including pregnant women and pediatric populations (age < 18 years). 
We did not set a criterion based on Covid-19 diagnosis definition, exposure ascertainment, 
or outcome definition because these were expected to be different and/or with limited rigor.
Search strategy
An experienced librarian (N.A.V.), with input from investigators, searched several 
databases for peer-reviewed manuscripts in English published between December 1, 2019, 
and April 6, 2020, including Ovid Medline In-Process & Other Non-Indexed Citations, Ovid 
Medline, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane 
Database of Systematic Reviews, and Scopus. Manual screening of references from the in-
cluded studies was performed [27]. All supplementary material and figures are located in a
digital research materials repository [27].
Selection process and data extraction
Search results were uploaded into an online software program (DistillerSR; Evidence Partners, 
Ottawa, ON, Canada). Reviewers, working independently and in duplicate, screened studies 
for eligibility using standardized and prepiloted instructions in a round of title and abstract 
and one of full-text screening. In round 1, disagreements were included; and in round 2, 
disagreements were resolved by consensus or arbitration by a third investigator (F.H.S.). To 
identify articles with high probability of patient repetition, studies that were included after 
full-text screening followed a preliminary data extraction conducted by 2 pairs of investigators. 
We extracted the timeframes of each study, hospital(s), location(s), country of origin, and the 
list of authors. Next, the enrollment timeframes from the studies were plotted with the infor-
mation of the hospital(s). Studies without overlap in the plot were included for all outcomes. If 
studies overlapped, we analyzed outcomes reported by each study. If outcomes were repeated 
in overlapping studies, we included the data for outcomes (or frequency of comorbidities) from 
the study with the largest sample [27]. Data extraction was also performed in an independent 
and duplicated manner using a standardized and prepiloted.
Risk of bias and confidence in the body of evidence
For case series, we modified 2 tools and analyzed: selection, ascertainment of outcomes 
and exposures, causality, and reporting [28, 29]. For case control studies, the Newcastle-
Ottawa Scale was used [30]. The quality of evidence for each outcome was determined using 
the Grading of Recommendations Assessment, Development and Evaluation approach [31]. 
Both risk of bias and overall quality of evidence assessment were performed independently 
and in duplicate. Disagreements were resolved by consensus between the 2 reviewers, or by 
arbitration by a third author (R.R.G.) [27]. Full details are listed elsewhere [27].
Data synthesis
We estimated the full-text screening inter-rater reliability with the Cohen’s kappa sta-
tistic. To estimate the prevalence, we used a binomial-normal model for meta-analysis of 
proportions (i.e., generalized linear mixed model) [32, 33]. We calculated the relative risk 
(RR) for each outcome and performed a meta-analysis results using a random-effect models 
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Figure 1. Flow chart of the selection process.
and the restricted maximum-likelihood estimator [34]. Meta-analysis of unadjusted and 
adjusted estimates was not combined. We were unable to calculate adjusted estimates be-
cause of scarcity of data. Inconsistency for each outcome, not attributable to chance, was 
assessed visually using forest plots and estimated using the percentage of variance in a 
meta-analysis that is attributable to study heterogeneity (I2) statistic: I2 < 25% and > 75% 
reflects low and high inconsistency, respectively [35]. All statistical analyses were performed 
in R (R Foundation for Statistical Computing, Vienna, Austria) [36].
Analysis of subgroups and sensitivity
Details on all predefined and nonpredefined subgroup and sensitivity analyses are listed 
separately [27]. To identify confounders, we designed a directed acyclic graph (DAG) in R 
[27, 37-41].
Results
Search strategy yielded 5484 studies. After deduplication and screening, 122 studies ful-
filled our selection criteria (Fig.  1). Full-text screening inter-observer agreements were 
substantial (k = 0.77, 0.80, and 0.84 for each pair of reviewers). We identified 93 articles at 
high probability of repeating patients. From those, we fully excluded 57 (47%), and partially 
(some outcomes included) excluded some outcomes in 36 (30%) [27]. Ultimately, 65 (15 794 
patients) were included in our analysis. Overall, 18 (28%) studies had low risk of bias, 
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3 (4%) had some concerns, and 44 (68%) had high risk. For prevalence, 40 (62%) studies 
resulted at low risk of bias, 1 (1%) at some concerns, and 24 (37%) at high risk. Overall con-
fidence in the body of evidence is graded as low [27]. We did not assess risk of publication 
bias through the funnel plot because of the limited number of studies [22].
Characteristics of included studies
Most studies were retrospective case series (97%) performed at a single center (63%) in 
China (71%), with inpatients (43%) diagnosed with Covid-19 using RT-PCR (Table 1) (97%). 
Most articles described treatments, which included standard of care (38%) and supple-
mental antiviral therapy (42%). Study length was reported in most studies (75%; 9-65 days). 
Percentage of males varied between 0 and 88, and the mean age ranged from 33 to 75 years. 
A total of 5 studies (8%) reported ethnicity.
Only 69% of studies reported their definition of severity. Among those that did report 
severity definitions, 78% of their definitions were derived from established guidelines [27]. 
Moreover, only 6 of the studies (9%) described the subtype of diabetes (type 2 diabetes), and 
1 study (2%) defined the subtype of hypertension (primary hypertension). Finally, none of 
the included studies provided a definition for diabetes or hypertension.
Prevalence and risks of diabetes and hypertension
Quantitative synthesis. The overall prevalence was 12% (95% confidence interval [CI], 
10-15; n = 12 870; I2: 89%) for diabetes, 17% (95% CI, 13-22; n = 12 709; I2: 95%) for hyper-
tension, and 12% (95% CI, 6-22; n = 54; I2: 0%) for coexisting diabetes and hypertension 
(Fig. 2). The RR of patients with diabetes to develop our outcomes of interest were: Covid-
19 severity (1.50; 95% CI, 0.90-2.50; n = 1991; I2: 74%; P = .118), ICU admission (1.96; 95% 
CI, 1.19-3.22; n = 8890; I2: 80%; P = .007), and mortality (2.78; 95% CI, 1.39-5.58; n = 2058; 
I2: 75%; P = .004). For patients with hypertension: Covid-19 severity (1.48; 95% CI, 0.99-
2.23; n = 2023; I2: 69%; P = .058), ICU admission (2.95; 95% CI, 2.18-3.99; n = 1737; I2: 0%; 
P < .001), and mortality (2.39; 95% CI, 1.54-3.73; n = 3107; I2: 66%; P < .001). Furthermore, 
for patients with diabetes and hypertension, RR for Covid-19 severity was 10 (95% CI, 0.94-
105.92; n = 22; I2: not applicable; P = .056).
Narrative synthesis. Adjusted and unadjusted estimates for mortality (hazard ratio) in 
patients with diabetes were nonconclusive in 2 studies (0.75; 95% CI, 0.38-1.50; n = 416; 
P = .420) [42] and (1.09; 95% CI, 0.57-2.08; n = 339; P = .799) [43]. Moreover, an adjusted 
odds ratio for severe Covid-19 in patients with hypertension reported by a study was 2.71 
(95% CI, 1.32-5.59; n = 487; P = .007) [43]. Finally, another study reported an unadjusted 
hazard ratio that was inconclusive in determining the risk of severe Covid-19 associated 
with diabetes and hypertension (1.49; 95% CI, 0.92-2.44; n = 339; P = .109) [43]. Adjusted 
estimates are displayed along with our results for visual comparison in Fig. 3.
Sensitivity analyses
Predefined sensitivity analyses. After excluding studies at high risk of bias, the overall 
prevalence of diabetes (12.4%; 95% CI, 9.5-16; n = 12 077/12 870; I2: 93%; 22/31 studies) and 
hypertension (16.8%;95% CI, 11.5-23.7; n = 11 912/12 709; I2: 96%; 25/37 studies) was sim-
ilar. Moreover, in patients with hypertension, RR for severe Covid-19 remained the same but 
heterogeneity decreased (1.40; 95% CI, 0.65-3.00; n = 53/2023; I2: 0%; P = .389, 2/8 studies), 
whereas the risk for ICU admission decreased (2.62; 95% CI, 1.45-4.75; n = 143/1733; I2:15%; 
P = .001; 2/3 studies), and mortality increased (3.24; 95% CI, 1.27-8.28; n = 32/2063; I2: 9%; 
P = .014; 2/5 studies).
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After excluding single-center studies from the analysis, RR for severe Covid-19 among 
patients with diabetes increased (2.1; 95% CI, 1.20-3.66; n = 1613/1991; I2: 33%; P = .009; 2/6 
studies). In contrast, RR for ICU admission decreased (1.80; 95% CI, 0.90-3.61; n = 8752/8890; 
I2: 88%; P = .096; 2/3 studies). Additionally, in patients with hypertension, RR for severe Covid-
19 increased (2.55; 95% CI, 2.06-3.16; n = 1613/2023; I2: 0%; P < .0001; 2/8 studies); for ICU ad-
mission decreased (2.70; 95% CI, 1.58-4.60; n = 1595/1733; I2: 20%; P = .0002; 2/3 studies); and, 
for mortality increased (3.32; 95% CI, 1.36-8.10; n = 1595/2063; I2: 13%; P = .008; 2/5 studies).
Non-predefined sensitivity analyses
Because there was high variability in the definition of severe Covid-19 used by authors, we 
analyzed the risk for severe Covid-19 after including only those studies that defined severity 
according to the World Health Organization definition [44] or that of the novel coronavirus 
Disease and outcome
Diabetes
     Severe COVID−19
     ICU admission
     Mortality
Hypertension
     Severe COVID−19
     ICU admission
     Mortality
Diabetes and Hypertension
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1.48   ( 0.99 − 2.23 )
2.71   ( 1.32 − 5.59 )
2.95   ( 2.18 − 3.99 )
2.39   ( 1.54 − 3.73 )
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Figure 3. Risk estimates for severe Covid-19, intensive care unit admission, and 
mortality. RR = relative risk. HR = hazard ratio. *Adjusted for age, preexisting cardiovas-
cular disease (hypertension, coronary heart disease, and chronic heart failure), cerebrovas-
cular disease, chronic obstructive pulmonary disease, renal failure, cancer, acute respiratory 
distress syndrome, creatine levels, NT-proB-type natriuretic peptide levels, and cardiac 
injury. **Adjusted for time to admission.
Prevalence of Diabetes
   Overall
      Outpatient
      Inpatient
           Severe COVID−19
      Non−survivors
Prevalence of Hypertension
   Overall
      Outpatient
      Inpatient
           Severe COVID−19
Prevalence of Diabetes and Hypertension
   Overall






































0.12 95% CI ( 0.10 − 0.15 )
0.03 95% CI ( 0.02 − 0.04 )
0.12 95% CI ( 0.10 − 0.15 )
0.18 95% CI ( 0.16 − 0.20 )
0.30 95% CI ( 0.19 − 0.43 )
0.17 95% CI ( 0.13 − 0.22 )
0.05 95% CI ( 0.03 − 0.06 )
0.21 95% CI ( 0.17 − 0.26 )
0.32 95% CI ( 0.16 − 0.54 )
0.12 95% CI ( 0.06 − 0.22 )
0.20 95% CI ( 0.05 − 0.54 )
0 0.1 0.2 0.3 0.4 0.5 0.6
Figure 2. Prevalence of diabetes and hypertension, overall and by subgroups. Five 
studies in the diabetes, and 3 in the hypertension overall prevalence were not included in 
subgroups as they did not specify their setting. Nonsurvivor patients in diabetes were not 
included in the overall prevalence. Severe Covid-19 patients are also included in the inpatient 
subgroup prevalence; these patients were those from studies that included only severe, 
critical, or ICU patients, with or without acute respiratory distress syndrome. All patients 
included in the overall prevalence for the diabetes and hypertension population were in-
patients. Covid-19, coronavirus disease 2019; ICU, intensive care unit.
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pneumonia prevention and control program (6th ed.) [27, 45]. The RR resulted in similar 
estimates but decreased heterogeneity in diabetes (0.97; 95% CI, 0.65-1.46; n = 335; I2: 0%; 
P = .886), and hypertension (1.03; 95% CI, 0.67-1.57; n = 345; I2: 38%; P = .909). The com-
plete description of sensitivity analysis is provided separately [27].
Minimal sufficient adjustment sets
According to our DAG, conditioning age and obesity is necessary to analyze the effect of dia-
betes on mortality, whereas for hypertension, age, diabetes, and obesity are necessary [27].
Discussion
Main findings
Our results suggest an overall prevalence of 12% and 17% for diabetes and hypertension 
(respectively) among nonpregnant, adult patients with Covid-19, respectively. Additionally, 
these comorbidities were associated with an increased risk for ICU admission and mor-
tality. We found an overwhelming proportion of studies at high risk of data repetition, which 
indicates a high risk of misrepresentation of estimates in previous systematic reviews that 
did not address this issue [16, 18-20]. The body of evidence comprises observational studies 
at moderate to high risk of bias yielding low confidence in the estimates.
Strengths and limitations
We developed a methodology to identify publications at high risk of patient repetition, 
which, compared with previous systematic reviews, provides a major strength to the cur-
rent analysis [16, 18-20]. Moreover, we also analyzed and grouped the various definitions 
used for severe Covid-19. From this, we conclude that this outcome lacks interpretability 
and therefore clinical significance because of the large heterogeneity in the definitions used. 
Hence, previous systematic reviews that have analyzed this outcome individually or as part 
of a composite, suffer from this limitation [16, 18-20]. Furthermore, although we could not 
perform a thorough isolation of the effect of comorbidities, we identified major confounders 
of our estimates using DAG [46].
Our study has several limitations. The effects of diabetes and hypertension in univar-
iate analysis cannot be attributed only to these exposures because, aside from possible 
confounders, patients may have had other comorbidities. To overcome this limitation, we 
extracted data from reported multivariate analyses. However, because their scarcity, we 
could not synthesize adjusted estimates. Second, most published studies are sourced from 
China and may be less generalizable to populations in other parts of the world. Moreover, 
3 of the included studies provided data on demographic or biochemical parameters such as 
blood pressure values, glycemic control markers, duration of disease, or smoking; however, 
we could not perform an adjusted analysis because these studies did not coincide with the 
assessed outcomes. Finally, auxiliary reasons for the observed risks could be a higher prev-
alence of obesity, cardiovascular, and renal disease in these patients. Additionally, elderly 
individuals are overrepresented among Covid-19 patients requiring hospital admission and 
critical care, where diabetes and hypertension is highest. Thus, the risks attributed to these 
comorbidities in relation to Covid-19 might be confounded, as our DAG suggests [27].
Comparison with previous studies
Diabetes. Two smaller reviews noted a prevalence of diabetes between 10% and 11.9% in 
Covid-19, comparable to our estimates [16, 17]. However, our estimates are lower than those 
reported by Shi et al. of 14.3% [43]. Furthermore, compared with the 9.3% global community 
prevalence of diabetes [47], our study found a 12% prevalence, suggesting a higher figure. In 
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contrast to author-defined severe Covid-19, dichotomous outcomes of disease severity such 
as ICU admission and mortality were significantly elevated (~2- and ~3-fold, respectively) in 
diabetes. This is of particular interest because Huang et al. noted an increased risk of a com-
posite poor outcome in patients with diabetes, which included severe Covid-19 as one of the 
outcomes. However, our analysis suggests that severe Covid-19 is a largely heterogenous out-
come that lacks interpretability and may not accurately reflect the outcomes of interest [20].
Additionally, 1 study of 1382 Covid-19 patients with diabetes found a 2.79-fold risk of ad-
mission to the ICU [48], higher than our findings of 1.96-fold in 8890 patients. However, the 
reported risk of Covid-19 mortality in diabetes was 2.85- to 3.21-fold, consistent with our 
findings [9, 48]. Other meta-analyses did not report ICU admission or mortality risk estimates 
[16, 49]. Comparatively, the SARS epidemic in 2003, also caused by a betacoronavirus, was 
associated with a 3-fold risk of poor outcomes in the presence of diabetes, the highest among 
all comorbidities [50].
The heightened Covid-19 risks in diabetes are multifactorial. Diabetes may facilitate the 
entry of SARS-CoV-2 by increased expression of ACE2 surface receptors because of the di-
sease itself and the treatment strategies used [10, 11, 51-53]. Furthermore, diabetes leads to 
dysregulation of immune responses by cytokines such as IL-6 and attenuating anti-inflam-
matory signaling leading to increased end-organ injury [10, 11, 54-56]. Given that obesity and 
diabetes often coexist [57], at least part of the heightened Covid-19 risks in diabetes could be 
attributed to comorbid obesity, an emerging independent risk factor for severe Covid-19 [58]. 
Furthermore, because diabetes is independently associated with comorbidities, Covid-19 acts 
as an additional insult to preexisting comorbidities. For instance, hypoglycemia, a comorbidity 
of diabetes, may be masked by hypoglycemia unawareness in asymptomatic Covid-19 carriers 
with diabetes mellitus with serious clinical consequences [6].
Hypertension. Initial reports indicated a 26% to 30% prevalence of hypertension in Covid-
19 patients [9, 59]. Published data from systematic reviews reported a 17.1% to 20% prev-
alence of hypertension in Covid-19, comparable to our estimates of 17% in our analysis of 
12 709 patients [16, 17]. In the inpatient setting, our results suggest that hypertension prev-
alence could be up to 26%, which is still lower compared with recent data from the United 
States of ~50% [60, 61]. Moreover, our estimates were lower than the 31.1% global prevalence 
of hypertension, which could suggest an average (or below average) risk of Covid-19 [62].
We found a nonconclusive risk of severe Covid-19 in hypertension. Other reports sug-
gest a higher risk of severe Covid-19 in hypertensives, of approximately 2.3-fold [17, 49]. 
However, after analyzing the important variation in the parameters used to define severity, 
we conclude that these estimates are noninterpretable. In contrast, the risk of ICU admis-
sion, which we consider a more reliable proxy of Covid-19 severity, was elevated in our anal-
ysis. Finally, we found an elevated risk of Covid-19 mortality associated with hypertension 
that was not described in other meta-analyses but is comparable to the 2.4- to 3.0-fold risk 
reported in primary studies [9, 63].
The observed risk of Covid-19 in patients with hypertension is likely multifactorial. The 
underlying immune dysregulation, with a higher propensity for an exaggerated immune 
response to viral exposure, resulting in a cytokine storm and end-organ injury could be a 
major contributor to this risk [64, 65]. Additional contributors may include a higher sympa-
thetic drive, hyperactivity of T-helper cells, increased ACE2 expression, and an enhanced 
angiotensin II/angiotensin 1-7 ratio reducing anti-inflammatory effects of the latter, and 
increased pro-inflammatory action of angiotensin II [66-70].
Implications for future research and clinical practice
Future studies of Covid-19 patients with diabetes or hypertension should report on patient 
characteristics, subtype of hypertension or diabetes, duration of disease, medications used, 
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and disease control markers. This information would not only be valuable for future system-
atic reviews but also assist frontline clinicians in individualizing the Covid-19 risks faced by 
their patients. Furthermore, future studies reporting multivariate analyses should consider 
our proposed minimal sufficient adjustment sets to avoid unnecessary or overadjustment 
of prognosticators. To date, the risk for severe Covid-19 faced by patients with diabetes 
and hypertension is unclear because of the large heterogeneity in the author definitions of 
Covid-19 severity. Until a universal definition of Covid-19 severity is adopted, we propose 
using the ICU admission rate as a more objective way to define severity.
Conclusion
Compared with previous reviews, our results suggest a lower prevalence of diabetes and 
hypertension in hospitalized Covid-19 patients. These patients face a higher risk of poor 
outcomes compared with those without these comorbidities. However, the body of evidence 
are at high risk of bias and provide low confidence in the estimates.
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